An mRNA cancer vaccine developed at University of Florida may have the ability to reprogram the immune system against glioblastoma, findings of a first-in-human trial showed.The trial — results of which appeared in Cell— included four adults with immunotherapy-resistant MGMT unmethylated glioblastoma.